Clene (CLNN) AI Stock Analysis

• Market Cap: $95.80M
• Dividend Yield: N/A
• Average Volume (3M): 114.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.58
• Revenue Growth: -49.17%
• EPS Growth: 23.37%
• Country: US
• Employees: 75
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.85
• Shares Outstanding: 10,333,980
• 10 Day Avg. Volume: 94,655
• 30 Day Avg. Volume: 114,899
• PEG Ratio: 0.02
• Price to Book (P/B): -4.17
• Price to Sales (P/S): 107.97
• P/FCF Ratio: -1.73
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: 352.11
• Enterprise Value/Gross Profit: 428.14
• Enterprise Value/Ebitda: -2.84
• 1Y Price Target: $28.40
• Price Target Upside: 206.36% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -2.38
• Revenue Forecast (FY): $173.00K

• Rating: 45 Neutral
• Price Target: $7.00 ▼(-24.49% Downside)

Clene's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, high net losses, and negative equity. While technical indicators suggest some potential for price recovery, the valuation remains unattractive due to ongoing losses and lack of dividends. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Innovative Product Pipeline

Clene's focus on innovative therapies for ALS and Alzheimer's, leveraging nanotechnology, positions it well in the biotech sector for long-term growth.

Strong Gross Profit Margin

A strong gross profit margin indicates efficient cost management and potential for profitability if revenue challenges are addressed.

Strategic Partnerships

Partnerships with larger firms and academic institutions provide financial support and expertise, enhancing Clene's revenue potential and market reach.

Negative Factors

Negative Equity

Negative equity indicates financial instability, raising concerns about the company's ability to sustain operations without restructuring or capital infusion.

Declining Revenues

Significant revenue decline suggests challenges in product commercialization and market penetration, impacting long-term financial health.

High Cash Burn

High cash burn rate indicates potential liquidity issues, necessitating additional capital or improved cash management to sustain operations.

Clene Business Overview & Revenue Model

Company Description

Clene Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for neurodegenerative diseases. The company specializes in the research and commercialization of its proprietary platform technology, which utilizes nanotechnology to create therapeutics aimed at treating conditions such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Clene operates within the biotechnology sector, concentrating on advanced drug development and clinical trials to bring new treatment options to patients in need.

How the Company Makes Money

Clene generates revenue primarily through the development and commercialization of its therapeutic products. The company focuses on advancing its lead compounds through clinical trials, which may eventually lead to regulatory approval and market entry. Revenue streams may arise from partnerships with larger pharmaceutical companies, including licensing agreements, milestone payments, and royalties on product sales once therapies are approved. Additionally, Clene may receive funding through grants, public offerings, and private investments to support its ongoing research and development efforts.

Clene Financial Statement Overview

Summary

Clene is facing considerable financial challenges with declining revenues, high net losses, and negative equity. The substantial operating losses and cash flow issues highlight the need for strategic restructuring or additional capital infusion. The biotechnology sector's inherent risk is amplified by Clene's financial instability.

Income Statement

Clene has experienced significant revenue fluctuations with a decline from $654,000 in 2023 to $342,000 in 2024, reflecting a -47.71% revenue growth rate. The gross profit margin is relatively strong at 79.53%, but the company has negative net profit and EBIT margins due to substantial losses, with a net loss of $39.4 million in 2024.

Balance Sheet

The company has a negative stockholders' equity of -$8.86 million, indicating financial distress. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt of $20.84 million suggests significant leverage. With equity being negative, the equity ratio is also negative, signaling potential insolvency risks.

Cash Flow

Operating cash flow remains deeply negative at -$21.33 million, with a slightly improved free cash flow position over the year. The free cash flow to net income ratio indicates severe cash burn issues, and financing cash flow has decreased, showing potential challenges in raising capital.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	214.00K	342.00K	654.00K	473.00K	723.00K	206.00K
Gross Profit	176.00K	272.00K	533.00K	447.00K	434.00K	141.00K
EBITDA	-26.50M	-33.69M	-43.24M	-25.60M	-8.34M	-16.96M
Net Income	-30.50M	-39.40M	-49.50M	-29.92M	-9.74M	-19.28M
Balance Sheet
Total Assets	22.31M	27.34M	52.34M	44.49M	63.06M	68.24M
Cash, Cash Equivalents and Short-Term Investments	7.92M	12.15M	35.00M	23.32M	50.29M	59.27M
Total Debt	21.31M	20.84M	32.16M	31.82M	24.04M	4.32M
Total Liabilities	34.67M	36.19M	38.95M	41.26M	50.47M	67.90M
Stockholders Equity	-12.36M	-8.86M	13.39M	3.24M	12.60M	341.00K
Cash Flow
Free Cash Flow	-18.61M	-21.34M	-30.50M	-44.19M	-35.96M	-19.32M
Operating Cash Flow	-18.60M	-21.33M	-30.17M	-39.01M	-34.62M	-18.93M
Investing Cash Flow	-12.97K	6.32M	-1.50M	-10.16M	-1.33M	-387.00K
Financing Cash Flow	11.96M	-1.53M	42.16M	17.25M	27.11M	69.53M

Clene Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.27
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLNN, the sentiment is Positive. The current price of 9.27 is below the 20-day moving average (MA) of 9.55, above the 50-day MA of 8.42, and above the 200-day MA of 5.04, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 52.07 is Neutral, neither overbought nor oversold. The STOCH value of 60.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLNN.

Clene Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
DYAI	46 Neutral	$33.29M	―	-244.15%	―	-0.66%	-8.43%
CAMP	45 Neutral	$76.01M	-1.47	-172.70%	―	―	―
CLNN	45 Neutral	$95.80M	―	―	―	-49.17%	23.37%
AKTX	44 Neutral	$14.68M	―	-197.04%	―	―	―
ANTX	34 Underperform	$31.15M	-0.91	-45.91%	―	―	44.59%

Clene Corporate Events

Clene Inc. Reports Continued Financial Losses in Q3 2025

Clene Inc. is a clinical-stage pharmaceutical company focused on developing nanotechnology therapeutics for neurological disorders, including ALS, MS, and Parkinson’s disease. In its latest earnings report, Clene Inc. revealed a continued struggle with financial losses, reporting a net loss of $8.8 million for the third quarter of 2025, compared to a $8.0 million loss in the same period last year. The company’s revenue remained minimal, with only $15,000 generated in the quarter, highlighting its ongoing reliance on external funding to support its operations. Clene’s financial position showed a decrease in cash and cash equivalents to $7.9 million as of September 30, 2025, down from $12.2 million at the end of 2024. The company also reported a significant stockholders’ deficit, which increased to $12.4 million by the end of the third quarter. Looking ahead, Clene Inc. faces substantial challenges in securing additional financing to continue its operations and advance its drug development programs. The management has implemented cost-saving measures and is exploring various funding options, but the company’s future remains uncertain as it seeks to overcome its financial hurdles.

Clene Enters Equity Distribution Agreement with Canaccord

Clene Inc., a company in the biotechnology sector, has entered into an equity distribution agreement with Canaccord Genuity LLC to sell up to $25 million in common stock. As of October 17, 2025, Clene has filed a prospectus supplement to offer an additional $18.88 million in shares, following previous sales totaling approximately $6.12 million, potentially impacting its financial strategy and market presence.

The most recent analyst rating on (CLNN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.

Clene Unveils Promising Clinical Data at ECTRIMS 2025

On September 25, 2025, Clene announced new clinical data at the ECTRIMS 2025 meeting, highlighting that their product CNM-Au8 improves brain energy metabolism in multiple sclerosis patients. This announcement could enhance Clene’s positioning in the pharmaceutical industry, potentially impacting stakeholders by showcasing the effectiveness of their treatment in a significant medical condition.

The most recent analyst rating on (CLNN) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.

Clene Expands Equity Distribution to Raise Capital

On April 28, 2025, Clene Inc. entered into an equity distribution agreement with Canaccord Genuity LLC to offer and sell shares of its common stock, aiming to raise up to $25,000,000. By September 5, 2025, the company had already sold shares worth approximately $3,706,213 and filed a prospectus supplement for an additional $6,280,000 of shares, reflecting its ongoing efforts to bolster financial resources.

The most recent analyst rating on (CLNN) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.

Clene Inc. Reports Q2 2025 Financial Results

Clene Inc. is a clinical-stage pharmaceutical company focused on developing novel nanotechnology therapeutics primarily for neurological disorders such as ALS, MS, and Parkinson’s disease. In its latest earnings report for the quarter ended June 30, 2025, Clene Inc. reported a net loss of $7.4 million, a slight improvement from the $6.8 million loss in the same quarter last year. The company’s revenue remains minimal, with total revenue of $27,000 for the quarter, reflecting a decline from the previous year’s $91,000. The company’s operating expenses have decreased, with research and development expenses dropping significantly, contributing to a reduced loss from operations. Clene Inc. continues to face financial challenges with a substantial accumulated deficit and limited cash reserves, raising concerns about its ability to continue as a going concern. The company is actively seeking additional funding through various means to support its operations and advance its drug development programs. Looking ahead, Clene Inc.’s management remains focused on securing the necessary resources to continue its research and development efforts and achieve its strategic goals in the pharmaceutical industry.

Clene Amends Notes and Secures New Financing

On August 13, 2025, Clene Inc. announced amendments to its December 2024 senior secured convertible promissory notes, extending the maturity date to February 13, 2027, and postponing the commencement of monthly principal repayments to September 13, 2026. Additionally, the company entered into a new note purchase agreement with AE Capital Limited and others, issuing $1.5 million in senior secured convertible promissory notes. These financial maneuvers aim to provide Clene with a cash runway into the first quarter of 2026, supporting its ongoing clinical programs. Clene also reported its second quarter 2025 financial results, highlighting a net loss of $7.4 million and cash reserves of $7.3 million as of June 30, 2025. The company is advancing its CNM-Au8 programs for ALS and MS, with significant FDA meetings scheduled for the third quarter of 2025, aiming for a new drug application submission for ALS by the end of 2025.

The most recent analyst rating on (CLNN) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.